Allogene licensor Cellectis faces patent lawsuit in the U.S.

[The Patent Application Process Important Paperwork and Necessary Tools for Success]

Cancer drug developer Allogene Therapeutics (NASDAQ:ALLO [https://seekingalpha.com/symbol/ALLO]) announced on Tuesday that its licensor, Cellectis (NASDAQ:CLLS [https://seekingalpha.com/symbol/CLLS]), is facing a lawsuit in the U.S. over allegations of patent infringement related to gene editing technology.

In a regulatory filing, Allogene (NASDAQ:ALLO [https://seekingalpha.com/symbol/ALLO]) said that privately held Factor Bioscience has filed the lawsuit in a federal court in Delaware, claiming that Cellectis’s (NASDAQ:CLLS [https://seekingalpha.com/symbol/CLLS]) TALEN-based gene-editing technology violated some of its patents.

The Paris-based company has informed Allogene (NASDAQ:ALLO [https://seekingalpha.com/symbol/ALLO]) about the lawsuit on Oct. 6, as it has inked an agreement to license Cellectis’ (NASDAQ:CLLS [https://seekingalpha.com/symbol/CLLS]) disputed technology for several of its CAR-T therapies.

“Although we are not a party to this litigation, we rely on the TALEN gene-editing technology licensed from Cellectis to engineer certain of our allogeneic CAR T cell product candidates, including cema-cel and ALLO-316,” the company said.

Noting that AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), another licensee [https://ir.allogene.com/node/11116/html] of Cellectis (NASDAQ:CLLS [https://seekingalpha.com/symbol/CLLS]), has been named as a defendant in the case, Allogene (NASDAQ:ALLO [https://seekingalpha.com/symbol/ALLO]) warned that Factor Bio could also target it as a commercial user of the technology.

MORE ON ALLOGENE THERAPEUTICS, CELLECTIS

* Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript [https://seekingalpha.com/article/4827813-allogene-therapeutics-inc-allo-presents-at-citis-smid-call-series-2025-transcript]
* Allogene Therapeutics: Important Catalysts Guided For Early 2026 [https://seekingalpha.com/article/4813784-allogene-therapeutics-stock-important-catalysts-guided-early-2026]
* Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4813395-allogene-therapeutics-inc-allo-q2-2025-earnings-call-transcript]
* Allogene, Pliant down as J.P. Morgan cuts to Underweight on uncertain outlook [https://seekingalpha.com/news/4503297-allogene-pliant-down-jp-morgan-downgrades]
* Allogene outlines clinical milestones with MRD data readout planned for first half 2026 as portfolio advances [https://seekingalpha.com/news/4485106-allogene-outlines-clinical-milestones-with-mrd-data-readout-planned-for-first-half-2026-as]